MedTrace Logo

Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder

NCT00608075 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2016-10-06

No results posted yet for this study

Summary

The purpose of the research is to study brain structure, function and chemistry of patients with bipolar disorder who are receiving lithium, an FDA-approved treatment for bipolar mania, in order to better understand who benefits from treatment and why they respond to medications. Studying this may help improve treatment and outcome in patients with bipolar disorder.

Conditions

Interventions

DRUG

lithium

600 mg - 1800 mg per day

DRUG

Lithium

600 - 1800 mg

Sponsors & Collaborators

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Caleb M Adler, MD · University of Cincinnati

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2015-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608075 on ClinicalTrials.gov